Home » Topics » BioWorld Science, Conferences

BioWorld Science, Conferences
RSS

Results of first-in-human study of NNC-0114-0005 reported

Dec. 10, 2012

Genentech presents phase II results for rontalizumab in patients with SLE

Dec. 10, 2012

REP-9AC in combination with immunostimulatory agents proves effective in HBV-infected patients

Dec. 10, 2012

Preliminary phase I data presented on MLN-0128 for advanced solid malignancies

Dec. 7, 2012

First-in-patient trial data updated for PF-03084014

Dec. 7, 2012

Type I interferon receptor 1 MAb evaluated in patients with scleroderma

Dec. 7, 2012

Varenicline as a potential treatment for methamphetamine dependence

Dec. 7, 2012

BGP-15 shows promising prophylactic and therapeutic effect in collagen-induced arthritis

Dec. 5, 2012

EZN-2208, a pegylated drug conjugate for brain tumors

Dec. 5, 2012

Rapid antidepressant effects seen for AZD-6765 in patients

Dec. 4, 2012

Popular Stories

Today's news in brief
BioWorld
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
New mechanism of action identified for QC-6352
BioWorld Science
QC-6352 is a small molecule developed to inhibit the histone demethylase 4 (KDM4) that has shown potent antitumoral activity and which has a derivative named...
First-in-class pan-inflammasome blocker for hidradenitis suppurativa
BioWorld Science
Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.
SCAN is core circuit affected in Parkinson’s disease
BioWorld
Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...